Literature DB >> 16772732

The role of opioid receptor phosphorylation and trafficking in adaptations to persistent opioid treatment.

Emma E Johnson1, MacDonald J Christie, Mark Connor.   

Abstract

Mu-opioid receptor activation underpins clinical analgesia and is the central event in the abuse of narcotics. Continued opioid use produces tolerance to the acute effects of the drug and adaptations that lead to physical and psychological dependence. Continued mu-receptor signaling provides the engine for these adaptations, with most evidence suggesting that chronic agonist treatment produces only limited alterations in primary mu-opioid receptor signaling. Here we examine agonist regulation of mu-opioid receptor function, and whether this is altered by chronic treatment. Receptor phosphorylation is thought to be the key initial event in agonist regulation of the mu-opioid receptor, providing a signal for acute receptor desensitization and also subsequent receptor resensitization. Morphine appears to produce qualitatively and quantitatively different mu-receptor phosphorylation than other agonists, but the consequences of this remain obscure, at least in neurons. There is no evidence that agonist-induced mu-opioid receptor phosphorylation changes in chronically morphine-treated animals, although receptor regulation appears to be altered. Thus, as receptor phosphorylation and resensitization appear to maintain continued signaling through the mu-opioid receptor, these two events are crucial in facilitating adaptations to chronic opioid treatment, and the possibility that agonist-specific phosphorylation can contribute to the development of different adaptations remains open. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16772732     DOI: 10.1159/000093044

Source DB:  PubMed          Journal:  Neurosignals        ISSN: 1424-862X


  16 in total

Review 1.  Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction.

Authors:  M J Christie
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

Review 2.  Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

Authors:  J L Scavone; R C Sterling; E J Van Bockstaele
Journal:  Neuroscience       Date:  2013-04-24       Impact factor: 3.590

Review 3.  Epigenetics of µ-opioid receptors: intersection with HIV-1 infection of the central nervous system.

Authors:  Patrick M Regan; Rajnish S Dave; Prasun K Datta; Kamel Khalili
Journal:  J Cell Physiol       Date:  2012-07       Impact factor: 6.384

4.  Desensitization and trafficking of μ-opioid receptors in locus ceruleus neurons: modulation by kinases.

Authors:  Seksiri Arttamangkul; Elaine K Lau; Hsin-Wei Lu; John T Williams
Journal:  Mol Pharmacol       Date:  2011-11-23       Impact factor: 4.436

5.  Decreased mu-opioid receptor signalling and a reduction in calcium current density in sensory neurons from chronically morphine-treated mice.

Authors:  Emma E Johnson; Billy Chieng; Ian Napier; Mark Connor
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

6.  Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.

Authors:  Ira L Mintzer; Mark Eisenberg; Maria Terra; Casey MacVane; David U Himmelstein; Steffie Woolhandler
Journal:  Ann Fam Med       Date:  2007 Mar-Apr       Impact factor: 5.166

Review 7.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

8.  G protein-coupled receptor-promoted trafficking of Gbeta1gamma2 leads to AKT activation at endosomes via a mechanism mediated by Gbeta1gamma2-Rab11a interaction.

Authors:  Alejandro García-Regalado; María Luisa Guzmán-Hernández; Iliana Ramírez-Rangel; Evelyn Robles-Molina; Tamas Balla; José Vázquez-Prado; Guadalupe Reyes-Cruz
Journal:  Mol Biol Cell       Date:  2008-08-13       Impact factor: 4.138

9.  Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.

Authors:  M F Divin; F A Bradbury; F I Carroll; J R Traynor
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

10.  Mu-opioid receptor redistribution in the locus coeruleus upon precipitation of withdrawal in opiate-dependent rats.

Authors:  Jillian L Scavone; Elisabeth J Van Bockstaele
Journal:  Anat Rec (Hoboken)       Date:  2009-03       Impact factor: 2.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.